All News
Warfarin and End-Stage Osteoarthritis
Dr. David Liew discusses abstract #0934 - "Warfarin Use and Risk of Knee and Hip Replacements" - presented at the 2020 ACR annual meeting.
Read Article
Ten-Year Analysis of Low-Dose Glucocorticoids in early RA
Abstract #1998 by C. Roubille et al from Montpellier, France is a 10-year prospective analysis that looked at the risk of severe outcomes related to very low-dose glucocorticoid in early rheumatoid arthritis from the ESPOIR cohort.
Read Article
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Read Article
FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat
Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovasc
Read Article
Answering questions on how COVID-19 affects rheumatic patients
As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.
Read Article
Links:
Links:
Links:
Links:
#BestACR20Tweets RT @KDAO2011 : FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Links:
Links:
Links:
